Guilhem Roubaud

Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)

S. Nénan, R. Cathomas, S. Gillessen, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

N. Agarwal, C. Corcoran, O. Sartor, 2020, Annals of Oncology.

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

E. Small, D. Rathkopf, D. Olmos, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer

R. Schiappa, G. Milano, G. Gravis, 2023, Pharmaceutics.

614MO Cabazitaxel (CBZ) activity in men with metastatic castration resistant prostate cancer (mCRPC) with and without DNA damage repair (DDR) defects

P. Barthélémy, K. Fizazi, A. Thiery-Vuillemin, 2020 .